Details for Patent: 9,732,075
✉ Email this page to a colleague
Which drugs does patent 9,732,075 protect, and when does it expire?
Patent 9,732,075 protects QUVIVIQ and is included in one NDA.
This patent has fifty-one patent family members in thirty-four countries.
Summary for Patent: 9,732,075
| Title: | Benzimidazole-proline derivatives |
| Abstract: | The present invention relates to compounds of the formula (I) ##STR00001## wherein Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b and (R.sup.5).sub.n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists. |
| Inventor(s): | Boss; Christoph (Allschwil, CH), Brotschi; Christine (Allschwil, CH), Gude; Markus (Allschwil, CH), Heidmann; Bibia (Allschwil, CH), Sifferlen; Thierry (Allschwil, CH), Williams; Jodi (Allschwil, CH) |
| Assignee: | IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) |
| Application Number: | 14/405,649 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 9,732,075
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF INSOMNIA | ⤷ Sign Up | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF INSOMNIA | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,732,075
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 12170748 | Jun 4, 2012 | |
| 13158520 | Mar 11, 2013 | |
| PCT Information | |||
| PCT Filed | June 03, 2013 | PCT Application Number: | PCT/IB2013/054567 |
| PCT Publication Date: | December 12, 2013 | PCT Publication Number: | WO2013/182972 |
International Family Members for US Patent 9,732,075
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2855453 | ⤷ Sign Up | PA2022518 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2855453 | ⤷ Sign Up | 301197 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2855453 | ⤷ Sign Up | 2022C/543 | Belgium | ⤷ Sign Up |
| European Patent Office | 2855453 | ⤷ Sign Up | 122022000059 | Germany | ⤷ Sign Up |
| European Patent Office | 2855453 | ⤷ Sign Up | LUC00279 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2855453 | ⤷ Sign Up | CA 2022 00041 | Denmark | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
